|Articles|October 1, 2006

InSite Vision submits azithromycin NDA

Alameda, CA-InSite Vision Inc. submitted a New Drug Application (NDA) to the FDA for a topical 1% azithromycin formulation (Aza-Site) for the treatment of bacterial conjunctivitis.

Alameda, CA-InSite Vision Inc. submitted a New Drug Application (NDA) to the FDA for a topical 1% azithromycin formulation (Aza-Site) for the treatment of bacterial conjunctivitis. The formulation is paired with InSite's patented DuraSite ophthalmic drug-delivery system, which increases ocular retention of the drug.

Two phase III studies showed that the formulation, through this delivery system, was safe, well tolerated, and efficacious in the treatment of bacterial conjunctivitis.

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

InSite Vision submits azithromycin NDA

Related Content

FDA guidance to help accelerate cell and gene therapies

The Residency Report: Cardiovascular risk scores as a window into ocular disease

Oculis phase 3 DIAMOND trials miss vision endpoints in diabetic macular edema

TearSolutions advances Lacripep into phase 2 following dual FDA designations in neurotrophic keratitis

Opuviz aflibercept biosimilar launches in Europe for retinal diseases

Latest CME

(COPE Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

Neurotrophic Keratitis Insights: An Interactive Corneal Sensitivity Testing Workshop

(CME Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

(COPE Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

(CME Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

Retina Updates in Montréal

PER Global Perspectives: The TROP2-Targeted ADC Landscape in NSCLC and How to Interpret the Evidence

Rapid Reviews in Retina™: Emerging Updates from Spring 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Interventional Dry Eye: A Stepwise Treatment & Management Approach

(CME Track) Community Collaborative Connections™: Optimizing the Collaborative Care of Neovascular Retinal Disease in a New Age of Treatment

(CME Track) Collaborating Across the Continuum™: Best Practices in Patient-Centric Team Management of XLRP

(CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

(CME Track) A Forward Look at Anti-VEGF Therapies: A Paradigm Shift in Neovascular Retinal Disease Management

(CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

(CME Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

(COPE Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

Navigating Ocular Toxicities: A Multidisciplinary Roadmap for Managing Adverse Events in Targeted Cancer Therapy

Rapid Reviews in Retina™: Emerging Updates from Fall 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Trending on Ophthalmology Times - Clinical Insights for Eye Specialists

Oculis phase 3 DIAMOND trials miss vision endpoints in diabetic macular edema

TearSolutions advances Lacripep into phase 2 following dual FDA designations in neurotrophic keratitis

The Residency Report: Cardiovascular risk scores as a window into ocular disease

Study links alcohol consumption to earlier advanced presbyopia in men

Outlook Therapeutics resubmits BLA for bevacizumab-vikg (ONS-5010/LYTENAVA)